Skip to main content
SpringerLink
Log in

Bekannt, aber zu wenig behandelt

Die Osteoporose der Frau

Osteoporosis in women — well known but not treated

  • FORTBILDUNG_ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die Osteoporose ist eine der häufigsten Erkrankungen der Frau in der Postmenopause. Liegt die Häufigkeit bei 50-Jährigen nur bei 12%, so hat bereits die Hälfte aller über 74-Jährigen eine Osteoporose. Orientieren Sie sich auf den folgenden Seiten, um rechtzeitig eine adäquate Therapie einleiten zu können.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Pfeilschifter J. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes. 2006;114:611–22

    CAS  PubMed  Google Scholar 

  2. Hadji P et al. The epidemiology of osteoporosis-Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int. 2013;110:52–7

    PubMed Central  PubMed  Google Scholar 

  3. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2011;7:65–78

    Article  Google Scholar 

  4. Seeman E et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone. 2010; 46:1038–42

    Article  CAS  PubMed  Google Scholar 

  5. Misra M, Klibanski A. Anorexia nervosa and bone. J Endocrinol. 2014;221:163–76

    Article  Google Scholar 

  6. Wisser J et al. Changes in bone density and metabolism in pregnancy. Acta Obstet Gynecol Scand. 2005;84:349–54

    Article  PubMed  Google Scholar 

  7. Lanham SA et al. Intrauterine programming of bone. Part 1: Alteration of the osteogenic environment. Osteoporos Int. 2008;19:147–56

    Article  CAS  PubMed  Google Scholar 

  8. Lanham SA et al. Intrauterine programming of bone. Part 2: Alteration of skeletal structure. Osteoporos Int 2008;19:157–67.

    Article  CAS  PubMed  Google Scholar 

  9. Kovacs CS. Kalzium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia. 2005;10:105–18

    Article  PubMed  Google Scholar 

  10. Wuertz C et al. Cross-sectional study of factors that influence the 25-hydroxyvitamin D status in pregnant women and in cord blood in Germany. Br J Nutr. 2013;110:1895–902

    Article  CAS  PubMed  Google Scholar 

  11. Wagner CL et al. Health characteristics and outcomes of two randomized vitamin D supplementation trials during pregnancy: a combined analysis. J Steroid Biochem Mol Biol. 2013;136:313–20

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Steib-Furno S et al. Pregnancy-related hip diseases: incidence and diagnoses. Joint Bone Spine. 2007;74:3738

    Google Scholar 

  13. Hellmeyer L et al. The use of i. v. bisphosphonate in pregnancy-associated osteoporosis—case study. Exp Clin Endocrinol Diabetes. 2007;115:139–42

    Article  CAS  PubMed  Google Scholar 

  14. Hellmeyer L et al. Quantitative ultrasonometry of the phalanges during pregnancy: a longitudinal study. Climacteric. 2006;9:446–51

    Article  CAS  PubMed  Google Scholar 

  15. Hadji P. Aromatasehemmer-induzierte Osteoporose. Möglichkeiten der Diagnostik, Prävention und Therapie. Osteologie. 2010;19:144–8

    Google Scholar 

  16. Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol. 2007;106:157–61

    Article  CAS  PubMed  Google Scholar 

  17. Rizzoli R et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int;2012;23:2567–76

    Article  CAS  PubMed  Google Scholar 

  18. Podsiadlo D, Richardson S. The timed „Up & Go“: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–8

    Article  CAS  PubMed  Google Scholar 

  19. Guralnik JM et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;32:556–61

    Article  Google Scholar 

  20. Krege JH et al. A simple method for determining the probability a new vertebral fracture is present in postmenopausal women with osteoporosis. Osteoporos Int. 2006;17: 379–86

    Article  CAS  PubMed  Google Scholar 

  21. O’Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician. 2005;71: 105–12

    PubMed  Google Scholar 

  22. Michaelsson K et al. Long term Kalzium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ. 2013;346:228

    Article  Google Scholar 

  23. Reid IR, Bristow SM, Bolland MJ. Cardiovascular Complications of Kalzium Supplements. J Cell Biochem. 2013;2014:25028

    Google Scholar 

  24. Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet. 1989;2:1104–5

    Article  CAS  PubMed  Google Scholar 

  25. Tsai KS et al. Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis. J Clin Invest. 1984;73:1668–72

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Bischoff-Ferrari HA et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257–64

    Article  CAS  PubMed  Google Scholar 

  27. Ralston SH et al. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int. 2011;88:485–94

    Article  CAS  PubMed  Google Scholar 

  28. Carmel AS et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is >/=33 ng/ml. Osteoporos Int. 2012;23:2479–87

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Holick MF et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97:1153–8

    Article  CAS  PubMed  Google Scholar 

  30. Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30

    Article  CAS  PubMed  Google Scholar 

  31. Kanis JA et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44:1049–54

    Article  CAS  PubMed  Google Scholar 

  32. Reid IR. Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol. 2015;11:418–28

    Article  CAS  PubMed  Google Scholar 

  33. Moreira LD et al. Physical exercise and osteoporosis: effects of different types of exercises on bone and physical function of postmenopausal women. Arq Bras Endocrinol Metabol. 2014;58:514–22

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interdisziplinäres Zentrum Palliativmedizin, Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, D-97080, Würzburg, Deutschland

    Heide Siggelkow

Authors
  1. Heide Siggelkow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heide Siggelkow.

Additional information

This article is part of a supplement not sponsored by the industry.

Interessenkonflikt

Die Autorin erklärt, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ. Sie legt folgende potenzielle Interessenkonflikte offen: Vortragshonorare: MSD, Lilly, Amgen, GSK, Servier; Advisory Board: MSD, Lilly, Amgen, Servier.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siggelkow, H. Die Osteoporose der Frau. MMW - Fortschritte der Medizin 157 (Suppl 3), 73–80 (2015). https://doi.org/10.1007/s15006-015-3301-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-3301-1

Keywords

Search

Navigation